Clinical trials: Cytomegalovirus Infection
Cytomegalovirus Retinitis, HIV Infections
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral…
- Trial name
- NCT00002355
- Testing
- Fomivirsen sodium
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection.
- Trial name
- NCT00017784
- Testing
- Valganciclovir
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Infections, HIV Infections
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109; formerly SDZ 89-109) when…
- Trial name
- NCT00002268
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz
Cytomegalovirus Infection
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.
- Trial name
- NCT02798692
- Testing
- Low dose HB-101, Medium dose HB-101, High dose HB-101
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hookipa Biotech GmbH
Cytomegalovirus Infection
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks.
- Trial name
- NCT00942305
- Testing
- Brincidofovir
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals